These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for CagriSema versus 11.8% with ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

Review the current Novo Nordisk AS ADR (NVO:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NVO is the best investment for you.

Newport-based technology consultancy de Novo Solutions is the fastest-growing private company in Wales in the annual Sunday ...